- Home
- EMPD vs RAPT Comparison
EMPD vs RAPT Comparison
Compare EMPD & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMPD
- RAPT
- Stock Information
- Founded
- EMPD 2020
- RAPT 2015
- Country
- EMPD United States
- RAPT United States
- Employees
- EMPD N/A
- RAPT N/A
- Industry
- EMPD
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- EMPD
- RAPT Health Care
- Exchange
- EMPD Nasdaq
- RAPT Nasdaq
- Market Cap
- EMPD 428.3M
- RAPT 498.4M
- IPO Year
- EMPD 2021
- RAPT 2019
- Fundamental
- Price
- EMPD $7.72
- RAPT $28.69
- Analyst Decision
- EMPD
- RAPT Buy
- Analyst Count
- EMPD 0
- RAPT 7
- Target Price
- EMPD N/A
- RAPT $35.14
- AVG Volume (30 Days)
- EMPD 1.1M
- RAPT 321.0K
- Earning Date
- EMPD 11-11-2025
- RAPT 11-11-2025
- Dividend Yield
- EMPD N/A
- RAPT N/A
- EPS Growth
- EMPD N/A
- RAPT N/A
- EPS
- EMPD N/A
- RAPT N/A
- Revenue
- EMPD $3,501,765.00
- RAPT N/A
- Revenue This Year
- EMPD N/A
- RAPT N/A
- Revenue Next Year
- EMPD N/A
- RAPT N/A
- P/E Ratio
- EMPD N/A
- RAPT N/A
- Revenue Growth
- EMPD N/A
- RAPT N/A
- 52 Week Low
- EMPD $6.50
- RAPT $5.67
- 52 Week High
- EMPD $11.37
- RAPT $32.35
- Technical
- Relative Strength Index (RSI)
- EMPD 50.04
- RAPT 77.62
- Support Level
- EMPD $7.37
- RAPT $24.34
- Resistance Level
- EMPD $8.10
- RAPT $32.35
- Average True Range (ATR)
- EMPD 0.37
- RAPT 2.74
- MACD
- EMPD 0.08
- RAPT 0.48
- Stochastic Oscillator
- EMPD 50.94
- RAPT 72.42
About EMPD Empery Digital Inc. Common stock
Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.